The recent approval and market entry of 223Ra chloride as an α-emitting therapeutic radiopharmaceutical [4] and successful application of 225Ac-labeled inhibitors of prostate-specific membrane antigen (PSMA) for treatment of prostate cancer [5] highlighted the clinical potential of α-therapy and led to a tremendous boost of attention for TAT. This evidence concerns the gene FOLH1 and Familial prostate cancer.